Details of the Drug Combination

General Information of Drug Combination (ID: DCVRQQ4)

Drug Combination Name
Mitomycin Sorafenib
Indication
Disease Entry Status REF
Mesothelioma Investigative [1]
Component Drugs Mitomycin   DMH0ZJE Sorafenib   DMS8IFC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: MSTO
Zero Interaction Potency (ZIP) Score: 4.06
Bliss Independence Score: 3.71
Loewe Additivity Score: 6.18
LHighest Single Agent (HSA) Score: 7.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mitomycin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Gastrointestinal cancer 2C11 Approved [2]
Pancreatic adenocarcinoma N.A. Approved [3]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Urinary bladder cancer N.A. Approved [3]
Urinary bladder neoplasm N.A. Approved [3]
Urinary system neoplasm N.A. Approved [3]
Urinary tract disease GC2Z Approved [3]
Bladder disease DC11-DC1Z Investigative [3]
Colon cancer 2B90.Z Investigative [3]
Mitomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [13]
------------------------------------------------------------------------------------
Mitomycin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Mitomycin Interacts with 274 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [15]
Alternative prion protein (PRNP) OTE85L1Q APRIO_HUMAN Increases Expression [16]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [16]
HLA class I histocompatibility antigen, C alpha chain (HLA-C) OTV38BUJ HLAC_HUMAN Decreases Expression [16]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Decreases Expression [16]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [16]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [16]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [16]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [16]
Nuclear transcription factor Y subunit alpha (NFYA) OTWFFOVH NFYA_HUMAN Increases Expression [16]
Ephrin type-A receptor 2 (EPHA2) OTI6QNX2 EPHA2_HUMAN Decreases Expression [16]
Replication factor C subunit 4 (RFC4) OTWALD2R RFC4_HUMAN Decreases Expression [16]
Matrix metalloproteinase-14 (MMP14) OT9C197Z MMP14_HUMAN Decreases Expression [16]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Increases Expression [16]
Small ribosomal subunit protein eS1 (RPS3A) OTUEP7CL RS3A_HUMAN Increases Expression [16]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Increases Expression [16]
Histone-binding protein RBBP7 (RBBP7) OTLB56HX RBBP7_HUMAN Increases Expression [16]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [17]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [18]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [18]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [18]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Increases Expression [18]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Increases Expression [18]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [18]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [18]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [18]
DNA damage-binding protein 2 (DDB2) OTO8HVVB DDB2_HUMAN Increases Expression [18]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [19]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [8]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [8]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [8]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [20]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Phosphorylation [21]
Transcription factor EC (TFEC) OTUST8MR TFEC_HUMAN Decreases Expression [8]
Regulator of G-protein signaling 16 (RGS16) OTBKZASI RGS16_HUMAN Decreases Expression [8]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [8]
HMG box-containing protein 1 (HBP1) OTDPGGDV HBP1_HUMAN Decreases Expression [8]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [8]
Myelin protein zero-like protein 1 (MPZL1) OTJSUUHR MPZL1_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [21]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [22]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [23]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [24]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [23]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [23]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [25]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [22]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Activity [26]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [27]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [28]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [27]
CD59 glycoprotein (CD59) OTSUMQDH CD59_HUMAN Increases Mutagenesis [29]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [30]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Activity [23]
rRNA 2'-O-methyltransferase fibrillarin (FBL) OTRODIE5 FBRL_HUMAN Affects Localization [31]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [8]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [32]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [33]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [33]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Decreases Expression [8]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [34]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [35]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [8]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [32]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [23]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [8]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [8]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [8]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [8]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [34]
Ras-related protein Rap-2b (RAP2B) OTD2NDQP RAP2B_HUMAN Decreases Expression [8]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Secretion [35]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [36]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [8]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [37]
Protein kinase C zeta type (PRKCZ) OTN2FE42 KPCZ_HUMAN Increases Cleavage [35]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Increases Expression [33]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [28]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [38]
Tripartite motif-containing protein 26 (TRIM26) OTS0DJIP TRI26_HUMAN Decreases Expression [8]
E3 ubiquitin-protein ligase TRIM32 (TRIM32) OTJOV0PG TRI32_HUMAN Decreases Expression [8]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [8]
Chromatin assembly factor 1 subunit B (CHAF1B) OTOMK4KH CAF1B_HUMAN Decreases Expression [8]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Decreases Expression [37]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [8]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [8]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [35]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Expression [38]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [8]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [8]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [8]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [8]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [34]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [8]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [8]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [8]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Decreases Expression [8]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [8]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [8]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [8]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [8]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [8]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Increases Ubiquitination [21]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [8]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [8]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [8]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [8]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [8]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [8]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [8]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [8]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Affects Response To Substance [11]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [11]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Affects Response To Substance [11]
Fanconi-associated nuclease 1 (FAN1) OT1LM1HZ FAN1_HUMAN Increases Response To Substance [39]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Affects Response To Substance [11]
CD9 antigen (CD9) OT2184XU CD9_HUMAN Affects Response To Substance [11]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1) OT2E7A6W KANK1_HUMAN Affects Response To Substance [11]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [11]
Mitochondrial fission 1 protein (FIS1) OT2HL10J FIS1_HUMAN Affects Response To Substance [11]
Cytoplasmic aconitate hydratase (ACO1) OT2VUR7L ACOHC_HUMAN Affects Response To Substance [11]
Syncytin-2 (ERVFRD-1) OT3064D7 SYCY2_HUMAN Affects Response To Substance [11]
Protein FAM171A1 (FAM171A1) OT33BHEP F1711_HUMAN Affects Response To Substance [11]
Sister chromatid cohesion protein PDS5 homolog A (PDS5A) OT34P56Z PDS5A_HUMAN Affects Response To Substance [11]
Excitatory amino acid transporter 3 (SLC1A1) OT3B9M6W EAA3_HUMAN Affects Response To Substance [11]
Syntabulin (SYBU) OT3FQV7N SYBU_HUMAN Affects Response To Substance [11]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [11]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Affects Response To Substance [11]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Response To Substance [40]
Pyridoxal kinase (PDXK) OT40AJ5J PDXK_HUMAN Affects Response To Substance [11]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Affects Response To Substance [11]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Affects Response To Substance [11]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Response To Substance [41]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Affects Response To Substance [11]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Affects Response To Substance [11]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Affects Response To Substance [11]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [11]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Affects Response To Substance [11]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Increases Response To Substance [42]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [11]
Transcriptional regulator ATRX (ATRX) OT77RSQW ATRX_HUMAN Affects Response To Substance [11]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [11]
Ras-related protein Rab-17 (RAB17) OT7NBUGQ RAB17_HUMAN Affects Response To Substance [11]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Affects Response To Substance [11]
Pirin (PIR) OT8ALXHU PIR_HUMAN Affects Response To Substance [11]
Myelin proteolipid protein (PLP1) OT8CM9CX MYPR_HUMAN Affects Response To Substance [11]
Protein-S-isoprenylcysteine O-methyltransferase (ICMT) OT8CNKBO ICMT_HUMAN Affects Response To Substance [11]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Response To Substance [11]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E) OT8GPFT5 2A5E_HUMAN Decreases Response To Substance [43]
cAMP-dependent protein kinase inhibitor alpha (PKIA) OT8M5GVO IPKA_HUMAN Affects Response To Substance [11]
Melanoma-associated antigen 12 (MAGEA12) OT8ULELL MAGAC_HUMAN Affects Response To Substance [11]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A) OT9297OG 2ABA_HUMAN Decreases Response To Substance [43]
Tissue factor pathway inhibitor (TFPI) OTA0FX16 TFPI1_HUMAN Affects Response To Substance [11]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2) OTAKUO27 ACOT2_HUMAN Affects Response To Substance [11]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [44]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Affects Response To Substance [11]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Affects Response To Substance [11]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [11]
ETS domain-containing protein Elk-3 (ELK3) OTBM9BHT ELK3_HUMAN Affects Response To Substance [11]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Affects Response To Substance [11]
Protein PRRC2C (PRRC2C) OTBX3MXM PRC2C_HUMAN Affects Response To Substance [11]
Melanocyte protein PMEL (PMEL) OTCDDHHM PMEL_HUMAN Affects Response To Substance [11]
BMP and activin membrane-bound inhibitor homolog (BAMBI) OTCEJ8W5 BAMBI_HUMAN Affects Response To Substance [11]
Creatine kinase U-type, mitochondrial (CKMT1A) OTCINHH5 KCRU_HUMAN Affects Response To Substance [11]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) OTCJ458Q AT1A1_HUMAN Affects Response To Substance [11]
CD166 antigen (ALCAM) OTCO4LP7 CD166_HUMAN Affects Response To Substance [11]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [11]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Response To Substance [45]
Collagen alpha-3(IX) chain (COL9A3) OTCUJOEK CO9A3_HUMAN Affects Response To Substance [11]
A-kinase anchor protein 12 (AKAP12) OTCVRDDX AKA12_HUMAN Affects Response To Substance [11]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Affects Response To Substance [11]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [11]
dTDP-D-glucose 4,6-dehydratase (TGDS) OTEOFLOS TGDS_HUMAN Affects Response To Substance [11]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Affects Response To Substance [11]
Ras association domain-containing protein 1 (RASSF1) OTEZIPB7 RASF1_HUMAN Increases Response To Substance [46]
Protocadherin Fat 1 (FAT1) OTF174DH FAT1_HUMAN Affects Response To Substance [11]
Midkine (MDK) OTF24HKC MK_HUMAN Affects Response To Substance [11]
Serine/arginine-rich splicing factor 1 (SRSF1) OTF61HOV SRSF1_HUMAN Affects Response To Substance [11]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C) OTF7CGO2 2A5G_HUMAN Increases Response To Substance [43]
G antigen 7 (GAGE7) OTF8BTR9 GAGE7_HUMAN Affects Response To Substance [11]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [11]
Catenin alpha-1 (CTNNA1) OTFC725Z CTNA1_HUMAN Affects Response To Substance [11]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [11]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [11]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Affects Response To Substance [11]
Tudor domain-containing protein 3 (TDRD3) OTG83E2C TDRD3_HUMAN Affects Response To Substance [11]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Affects Response To Substance [11]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [11]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [47]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [11]
Transmembrane protein 156 (TMEM156) OTH7YJID TM156_HUMAN Affects Response To Substance [11]
Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C) OTHAWK8C JHD2C_HUMAN Affects Response To Substance [11]
Unconventional myosin-X (MYO10) OTHB78ZQ MYO10_HUMAN Affects Response To Substance [11]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Affects Response To Substance [11]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Affects Response To Substance [11]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [11]
Protein S100-A11 (S100A11) OTI57KDN S10AB_HUMAN Affects Response To Substance [11]
Protein S100-A10 (S100A10) OTI71243 S10AA_HUMAN Affects Response To Substance [11]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [11]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Increases Response To Substance [48]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [11]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Affects Response To Substance [11]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Affects Response To Substance [11]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [11]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Affects Response To Substance [11]
Hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1) OTJQL0I3 HEY1_HUMAN Affects Response To Substance [11]
E3 ubiquitin-protein ligase MYLIP (MYLIP) OTL0PFGV MYLIP_HUMAN Affects Response To Substance [11]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Affects Response To Substance [11]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2) OTLNA39Z NMT2_HUMAN Affects Response To Substance [11]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [49]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Affects Response To Substance [11]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [11]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Affects Response To Substance [11]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Affects Response To Substance [11]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Affects Response To Substance [11]
Cysteine-rich hydrophobic domain-containing protein 2 (CHIC2) OTNE3T6Z CHIC2_HUMAN Affects Response To Substance [11]
Inositol monophosphatase 2 (IMPA2) OTNFB9YN IMPA2_HUMAN Affects Response To Substance [11]
Neural cell adhesion molecule L1 (L1CAM) OTNWAQ4Y L1CAM_HUMAN Affects Response To Substance [11]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Affects Response To Substance [50]
Kynurenine--oxoglutarate transaminase 3 (KYAT3) OTO4U2QK KAT3_HUMAN Affects Response To Substance [11]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [11]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Affects Response To Substance [11]
SH3 domain-binding protein 5 (SH3BP5) OTOOEGUJ 3BP5_HUMAN Affects Response To Substance [11]
Glutathione S-transferase Mu 4 (GSTM4) OTOTF8DU GSTM4_HUMAN Affects Response To Substance [11]
Ras-related protein Rab-20 (RAB20) OTP9OOVS RAB20_HUMAN Affects Response To Substance [11]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Affects Response To Substance [11]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [11]
Kazrin (KAZN) OTPM7BYM KAZRN_HUMAN Affects Response To Substance [11]
DNA-binding protein inhibitor ID-4 (ID4) OTPMJ39I ID4_HUMAN Affects Response To Substance [11]
Centrosomal protein of 57 kDa (CEP57) OTPOHLIX CEP57_HUMAN Affects Response To Substance [11]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [11]
Dermatan-sulfate epimerase (DSE) OTQ108VJ DSE_HUMAN Affects Response To Substance [11]
Adhesion G-protein coupled receptor G1 (ADGRG1) OTQBB8NT AGRG1_HUMAN Affects Response To Substance [11]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A) OTQDYH8E ASM3A_HUMAN Affects Response To Substance [11]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [11]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Affects Response To Substance [11]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Affects Response To Substance [11]
Dr1-associated corepressor (DRAP1) OTRWLF6D NC2A_HUMAN Affects Response To Substance [11]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [11]
Terminal nucleotidyltransferase 5A (TENT5A) OTSYF511 TET5A_HUMAN Affects Response To Substance [11]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [11]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Increases Response To Substance [51]
Calcium-dependent secretion activator 2 (CADPS2) OTV1FW0M CAPS2_HUMAN Affects Response To Substance [11]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Affects Response To Substance [11]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [49]
Ensconsin (MAP7) OTVSSJ33 MAP7_HUMAN Affects Response To Substance [11]
Protein artemis (DCLRE1C) OTW3KB1I DCR1C_HUMAN Decreases Response To Substance [12]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [11]
Protein mago nashi homolog (MAGOH) OTWRYTOX MGN_HUMAN Affects Response To Substance [11]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Affects Response To Substance [11]
Acylamino-acid-releasing enzyme (APEH) OTX258QE ACPH_HUMAN Affects Response To Substance [11]
Hematopoietic lineage cell-specific protein (HCLS1) OTX7WGYN HCLS1_HUMAN Affects Response To Substance [11]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [11]
Long-chain fatty acid transport protein 3 (SLC27A3) OTXB60L7 S27A3_HUMAN Affects Response To Substance [11]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Affects Response To Substance [11]
Arginine vasopressin-induced protein 1 (AVPI1) OTXSBR60 AVPI1_HUMAN Affects Response To Substance [11]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [11]
Carbamoyl-phosphate synthase , mitochondrial (CPS1) OTXV8NSR CPSM_HUMAN Affects Response To Substance [11]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Affects Response To Substance [11]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Affects Response To Substance [11]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [11]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Affects Response To Substance [11]
LIM and calponin homology domains-containing protein 1 (LIMCH1) OTYPC4XA LIMC1_HUMAN Affects Response To Substance [11]
Galectin-3 (LGALS3) OTYQT0ZI LEG3_HUMAN Affects Response To Substance [11]
L-dopachrome tautomerase (DCT) OTYVNTBG TYRP2_HUMAN Affects Response To Substance [11]
Epithelial discoidin domain-containing receptor 1 (DDR1) OTYW1SH8 DDR1_HUMAN Affects Response To Substance [11]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [11]
Suppressor of tumorigenicity 7 protein (ST7) OTZG8RC6 ST7_HUMAN Affects Response To Substance [11]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Response To Substance [49]
CTD small phosphatase-like protein (CTDSPL) OTZJ0CZK CTDSL_HUMAN Affects Response To Substance [11]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [11]
Eukaryotic translation initiation factor 5B (EIF5B) OTZTT22W IF2P_HUMAN Affects Response To Substance [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 274 DOT(s)
Indication(s) of Sorafenib
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [5]
Carcinoma 2A00-2F9Z Approved [5]
Clear cell renal carcinoma N.A. Approved [5]
Lung cancer 2C25.0 Approved [5]
Medullary thyroid gland carcinoma N.A. Approved [5]
Non-small-cell lung cancer 2C25.Y Approved [5]
Renal cell carcinoma 2C90 Approved [6]
Thyroid cancer 2D10 Approved [5]
Hepatocellular carcinoma 2C12.02 Phase 3 [6]
Myelodysplastic syndrome 2A37 Phase 2 [6]
Sorafenib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [57]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [57]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [58]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [57]
------------------------------------------------------------------------------------
Sorafenib Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [59]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [60]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [61]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [62]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [63]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [62]
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [64]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Sorafenib Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [65]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [66]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [67]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [67]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [65]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Sorafenib Interacts with 112 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [69]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Response To Substance [70]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Phosphorylation [71]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [72]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [73]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [73]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [74]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [75]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [75]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Decreases Expression [52]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [52]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [52]
GTPase NRas (NRAS) OTVQ1DG3 RASN_HUMAN Decreases Expression [52]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [52]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [52]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Decreases Expression [52]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [52]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [52]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [52]
Cyclin-dependent kinase 9 (CDK9) OT2B7OGB CDK9_HUMAN Decreases Expression [52]
Growth factor receptor-bound protein 2 (GRB2) OTOP7LTE GRB2_HUMAN Decreases Expression [52]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [52]
Interferon regulatory factor 5 (IRF5) OT8SIIAP IRF5_HUMAN Increases Expression [52]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [52]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [52]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [52]
Histone deacetylase 6 (HDAC6) OT9W9MXQ HDAC6_HUMAN Decreases Expression [52]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [73]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [76]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Decreases Expression [77]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Decreases Expression [53]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Ubiquitination [78]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B) OTL9I7LO GA45B_HUMAN Increases Expression [79]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [54]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [80]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [77]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Activity [81]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [82]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [83]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [84]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Decreases Activity [71]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [85]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [79]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [86]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [87]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Phosphorylation [77]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Activity [88]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Expression [84]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [89]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [81]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [69]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [90]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [53]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Activity [91]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Activity [92]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Phosphorylation [93]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [73]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [94]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [95]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [96]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [96]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [90]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [97]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Decreases Phosphorylation [71]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Decreases Phosphorylation [92]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [98]
Signal transducer and activator of transcription 5A (STAT5A) OTBSJGN3 STA5A_HUMAN Decreases Activity [99]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [100]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [82]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Decreases Phosphorylation [82]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Decreases Phosphorylation [82]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [81]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [101]
CCAAT/enhancer-binding protein delta (CEBPD) OTNBIPMY CEBPD_HUMAN Increases Expression [80]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [100]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [102]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [103]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [104]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [86]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Increases Expression [84]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Increases Expression [105]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [106]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [107]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [90]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Decreases Phosphorylation [92]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Cleavage [77]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [77]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [108]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [109]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [94]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Phosphorylation [110]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Decreases Expression [111]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [55]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Decreases Expression [112]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Decreases Expression [77]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [113]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [55]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [81]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1) OT50NR57 PINK1_HUMAN Increases Expression [78]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [54]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [114]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [115]
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD) OT37FKH0 CYLD_HUMAN Increases Expression [72]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [111]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [54]
E3 ubiquitin-protein ligase TRIM62 (TRIM62) OT15YO6N TRI62_HUMAN Affects Response To Substance [116]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Response To Substance [77]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Affects Response To Substance [70]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Decreases Response To Substance [117]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Affects Response To Substance [70]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Increases Response To Substance [106]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Response To Substance [118]
------------------------------------------------------------------------------------
⏷ Show the Full List of 112 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast and ovarian cancer syndrome DCX0W2S UWB1289+BRCA1 Investigative [119]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
3 Mitomycin FDA Label
4 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
5 Sorafenib FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
7 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
8 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
9 TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death. Life Sci. 2006 Feb 23;78(13):1499-507. doi: 10.1016/j.lfs.2005.07.021. Epub 2005 Oct 14.
10 Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):285-7. doi: 10.1007/s11596-007-0317-5.
11 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
12 Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
13 Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
14 In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
15 Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
16 Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
17 Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
18 Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
19 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
20 Trace levels of mitomycin C disrupt genomic integrity and lead to DNA damage response defect in long-term-cultured human embryonic stem cells. Arch Toxicol. 2015 Jan;89(1):33-45. doi: 10.1007/s00204-014-1250-6. Epub 2014 May 18.
21 Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget. 2015 Sep 22;6(28):25770-83. doi: 10.18632/oncotarget.4514.
22 Effects of mitomycin-C on normal dermal fibroblasts. Laryngoscope. 2006 Apr;116(4):514-7. doi: 10.1097/01.MLG.0000205590.62824.0A.
23 Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3 signaling. Toxicol Lett. 2021 Nov 1;352:61-69. doi: 10.1016/j.toxlet.2021.09.015. Epub 2021 Oct 5.
24 DNA polymerase kappa protects human cells against MMC-induced genotoxicity through error-free translesion DNA synthesis. Genes Environ. 2017 Jan 7;39:6. doi: 10.1186/s41021-016-0067-3. eCollection 2017.
25 In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005;115(3):219-28. doi: 10.1016/j.thromres.2004.09.001.
26 Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
27 Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts. Wound Repair Regen. 2010 Jan-Feb;18(1):59-69. doi: 10.1111/j.1524-475X.2009.00551.x. Epub 2009 Dec 11.
28 The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. 2010 Jul;37(6):2693-701. doi: 10.1007/s11033-009-9801-2. Epub 2009 Sep 13.
29 Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
30 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
31 Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
32 Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
33 Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.
34 Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3545-52. doi: 10.1167/iovs.04-1358.
35 Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 2000 Oct 1;158(2):125-32. doi: 10.1016/s0304-3835(00)00489-4.
36 Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci. 2008 Apr;102(2):232-40. doi: 10.1093/toxsci/kfm305. Epub 2007 Dec 20.
37 Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. doi: 10.1016/j.canlet.2005.05.043. Epub 2005 Jul 12.
38 Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas. Mol Vis. 2008 Jun 30;14:1222-8.
39 FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012 Jul 8;44(8):910-5. doi: 10.1038/ng.2347.
40 O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105. doi: 10.1016/j.taap.2005.06.009. Epub 2005 Jul 22.
41 Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876.
42 MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest. 1997 Dec 1;100(11):2873-80. doi: 10.1172/JCI119836.
43 PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
44 Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
45 Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
46 Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J Gastroenterol Hepatol. 2007 May;22(5):683-9. doi: 10.1111/j.1440-1746.2006.04676.x.
47 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
48 Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
49 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
50 [Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line]. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1349-52.
51 Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
52 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
53 Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro. 2014 Jun;28(4):552-61. doi: 10.1016/j.tiv.2014.01.002. Epub 2014 Jan 13.
54 The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007 Aug;27(15):5499-513. doi: 10.1128/MCB.01080-06. Epub 2007 Jun 4.
55 Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.
56 Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 2018 Sep;51:74-82. doi: 10.1016/j.tiv.2018.04.010. Epub 2018 Apr 24.
57 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
58 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
59 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
60 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
61 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
62 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
63 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
64 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
65 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
66 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
67 Drug Interactions Flockhart Table
68 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
69 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
70 The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
71 Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
72 Down-regulation of CYLD as a trigger for NF-B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2011 Jan;38(1):121-31.
73 Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011 Aug 1;82(3):216-26. doi: 10.1016/j.bcp.2011.04.011. Epub 2011 May 13.
74 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
75 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer. 2012 Sep 10;12:402.
76 The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
77 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
78 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
79 Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.
80 Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.
81 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
82 Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
83 Sorafenib inhibits transforming growth factor 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011 May;53(5):1708-18. doi: 10.1002/hep.24254.
84 Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
85 Sorafenib is an antagonist of the aryl hydrocarbon receptor. Toxicology. 2022 Mar 30;470:153118. doi: 10.1016/j.tox.2022.153118. Epub 2022 Feb 3.
86 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
87 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. doi: 10.1158/0008-5472.CAN-07-1473.
88 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30.
89 Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
90 Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7.
91 Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.
92 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.
93 Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.
94 Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.
95 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
96 Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
97 Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways. Chem Biol Interact. 2023 Jan 25;370:110329. doi: 10.1016/j.cbi.2022.110329. Epub 2022 Dec 22.
98 Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem. 2011 Jul;46(7):2845-51. doi: 10.1016/j.ejmech.2011.04.007. Epub 2011 Apr 14.
99 The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007 Sep;72(3):788-95. doi: 10.1124/mol.106.033308. Epub 2007 Jun 26.
100 Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
101 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.
102 The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
103 Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 2015 Feb;143(2):374-84. doi: 10.1093/toxsci/kfu235. Epub 2014 Nov 3.
104 Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther. 2009 Oct;8(20):1904-13. doi: 10.4161/cbt.8.20.9436. Epub 2009 Oct 6.
105 Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019 Sep 15;379:114665. doi: 10.1016/j.taap.2019.114665. Epub 2019 Jul 16.
106 Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.
107 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20;24(46):6861-9. doi: 10.1038/sj.onc.1208841.
108 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
109 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
110 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005 Oct 28;3:39. doi: 10.1186/1479-5876-3-39.
111 GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11;283(2):726-32. doi: 10.1074/jbc.M705343200. Epub 2007 Nov 8.
112 Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep;5(9):2378-87. doi: 10.1158/1535-7163.MCT-06-0235.
113 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
114 Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
115 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
116 TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-B pathway. Toxicol Appl Pharmacol. 2022 Jun 15;445:116035. doi: 10.1016/j.taap.2022.116035. Epub 2022 Apr 23.
117 Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma. Food Chem Toxicol. 2020 Aug;142:111475. doi: 10.1016/j.fct.2020.111475. Epub 2020 Jun 6.
118 Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells. Toxicol Appl Pharmacol. 2020 Sep 1;402:115117. doi: 10.1016/j.taap.2020.115117. Epub 2020 Jul 4.
119 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.